ATE324104T1 - Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung - Google Patents

Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung

Info

Publication number
ATE324104T1
ATE324104T1 AT02026576T AT02026576T ATE324104T1 AT E324104 T1 ATE324104 T1 AT E324104T1 AT 02026576 T AT02026576 T AT 02026576T AT 02026576 T AT02026576 T AT 02026576T AT E324104 T1 ATE324104 T1 AT E324104T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
controlled release
release pharmaceutical
containing mesalazine
Prior art date
Application number
AT02026576T
Other languages
English (en)
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11383159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324104(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Application granted granted Critical
Publication of ATE324104T1 publication Critical patent/ATE324104T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02026576T 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung ATE324104T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI001316A ITMI991316A1 (it) 1999-06-14 1999-06-14 Composizioni farmaceutiche orali a rilascio modificato di mesalazina

Publications (1)

Publication Number Publication Date
ATE324104T1 true ATE324104T1 (de) 2006-05-15

Family

ID=11383159

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00935194T ATE235234T1 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung
AT02026576T ATE324104T1 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00935194T ATE235234T1 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung

Country Status (18)

Country Link
US (1) US6773720B1 (de)
EP (2) EP1287822B1 (de)
JP (2) JP4727875B2 (de)
CN (2) CN1217665C (de)
AT (2) ATE235234T1 (de)
AU (1) AU5077200A (de)
CA (1) CA2377299C (de)
DE (2) DE60027608T2 (de)
DK (2) DK1287822T3 (de)
ES (2) ES2194732T3 (de)
HK (1) HK1046247B (de)
IT (1) ITMI991316A1 (de)
MX (1) MXPA01012888A (de)
NO (1) NO329402B1 (de)
PT (2) PT1287822E (de)
RU (1) RU2245148C2 (de)
TR (1) TR200200561T2 (de)
WO (1) WO2000076481A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2377301C (en) 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
ITMI20012599A1 (it) 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
FR2852843B1 (fr) * 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
GB0322848D0 (en) * 2003-09-30 2003-10-29 Alpharma Ltd Tetracycline controlled release pharmaceutical dosage form
AU2004312059A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
AU2004314731B2 (en) 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7700651B2 (en) 2006-07-19 2010-04-20 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
WO2008033124A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
US20100048519A1 (en) * 2006-09-13 2010-02-25 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis using aminosalicylate
CA2669229A1 (en) 2006-11-17 2008-05-29 Shire Development Inc. Method of treatment for inflammatory bowel disease
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2488163A1 (de) 2009-10-16 2012-08-22 Ranbaxy Laboratories Limited Pharmazeutische zusammensetzung aus mesalamin mit verzögerter freisetzung
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
EP2425826A1 (de) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazin-Tablette mit verbesserter Auflösung
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
EP2468264A1 (de) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Orale pharmazeutische Tablette zur gesteuerten Abgabe von Mesalazin und Verfahren zu deren Erhalt
EP2661266B1 (de) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Auf chemosensorischen rezeptorliganden basierende therapien
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
EP2800562A2 (de) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
AU2013229990B2 (en) * 2012-03-07 2017-07-06 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
US20150164920A1 (en) 2012-03-30 2015-06-18 Laboratorios Del Dr. Esteve S.A. Controlled release formulation comprising mesalamine
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2722058A1 (de) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Orale Feststoffzusammensetzung mit Farbstoffen für die Verwendung bei der endoskopischen Diagnose
CN105101956B (zh) 2013-01-05 2018-12-07 埃尔舍利克斯治疗公司 包含双胍的延迟释放组合物
WO2014129568A1 (ja) * 2013-02-22 2014-08-28 ゼリア新薬工業株式会社 腸溶錠
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US9763887B2 (en) 2013-03-15 2017-09-19 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
CN104922090B (zh) * 2015-07-03 2017-11-14 湖南方盛制药股份有限公司 美沙拉秦肠溶缓释微丸
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
EP3544638A1 (de) 2016-11-28 2019-10-02 Cosmo Technologies Ltd. Feste orale zusammensetzung mit farbstoffen
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3501503A1 (de) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Feste verabreichungszusammensetzung
EP3662895A1 (de) 2018-12-07 2020-06-10 Tillotts Pharma AG Verfahren zur herstellung von reduzierenden zuckerfreien 5-asa-tablettenkernen
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
CN112587506A (zh) * 2020-12-09 2021-04-02 南京森博医药研发有限公司 一种用于制备美沙拉嗪肠溶缓释胶囊的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
JPH02282323A (ja) * 1989-04-21 1990-11-19 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
JPH0624962A (ja) * 1992-07-09 1994-02-01 Green Cross Corp:The 腸溶徐放性製剤
JP2616252B2 (ja) * 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
WO1998026767A2 (en) * 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
CA2377301C (en) * 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions

Also Published As

Publication number Publication date
EP1287822A3 (de) 2003-03-19
ATE235234T1 (de) 2003-04-15
US6773720B1 (en) 2004-08-10
DE60001835D1 (de) 2003-04-30
MXPA01012888A (es) 2002-07-30
NO20016107D0 (no) 2001-12-14
EP1198226A1 (de) 2002-04-24
DE60001835T2 (de) 2003-11-13
EP1287822B1 (de) 2006-04-26
DE60027608T2 (de) 2007-04-26
CN1355694A (zh) 2002-06-26
ES2194732T3 (es) 2003-12-01
JP2003501458A (ja) 2003-01-14
RU2245148C2 (ru) 2005-01-27
NO20016107L (no) 2002-02-11
TR200200561T2 (tr) 2002-06-21
CA2377299A1 (en) 2000-12-21
WO2000076481A1 (en) 2000-12-21
AU5077200A (en) 2001-01-02
CN1217665C (zh) 2005-09-07
EP1287822A2 (de) 2003-03-05
DK1287822T3 (da) 2006-08-28
JP5235839B2 (ja) 2013-07-10
ITMI991316A1 (it) 2000-12-14
NO329402B1 (no) 2010-10-11
DK1198226T3 (da) 2003-07-21
PT1287822E (pt) 2006-07-31
CA2377299C (en) 2009-05-12
HK1085669A1 (zh) 2006-09-01
DE60027608D1 (de) 2006-06-01
CN1720919A (zh) 2006-01-18
JP2010024241A (ja) 2010-02-04
PT1198226E (pt) 2003-07-31
HK1046247B (zh) 2006-04-07
EP1198226B1 (de) 2003-03-26
CN100448448C (zh) 2009-01-07
JP4727875B2 (ja) 2011-07-20
ITMI991316A0 (it) 1999-06-14
HK1046247A1 (en) 2003-01-03
ES2262749T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
ATE235234T1 (de) Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
CA2158630A1 (en) Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability
RU2002102701A (ru) Стабильная пероральная образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
ATE78157T1 (de) Arzneimittel mit langsamer freisetzung.
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE68902531D1 (de) Dispergierbare zubereitung.
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
DE69710121D1 (de) Pharmazeutische Zusammensetzung aus stabilisierten lipophilen Matrizen mit kontrollierter Wirkstofffreisetzung
AR034435A1 (es) Agentes terapeuticos.
ES2194793T3 (es) Microcapsulas para la liberacion prolongada de farmacos.
DK0540813T3 (da) Acetazolamid-præparat med vedvarende afgift af aktivt stof
DE60029946D1 (de) Arzneimittel gegen glomerulosclerose
ITMI20000972A0 (it) Formulazioni farmaceutiche, a rilascio modificato, con elevata biodisponibilita', contenenti principi attivi ad attivita' antibiotica.
CO4910116A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles
DE60115450D1 (de) Pirlindolhydrochlorid-Matrixformulierungen mit verlängerter Wirkstofffreigabe
PA8531801A1 (es) Formulaciones estabilizadas que comprenden composiciones hidroliticamente inestables

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1287822

Country of ref document: EP